Sofdra® receives the International Hyperhidrosis Society Seal of Recognition(TM)

JMM

PHOENIX, USA – 10 November 2026: Commercial dermatology company, Botanix Pharmaceuticals Limited (ABN 70 009 109 755) (ASX:BOT, “Botanix” or “the Company”), is pleased to announce that Sofdra® (sofpironium) topical gel, 12.45% is a recipient of the International Hyperhidrosis Society Seal of Recognition™. This is the first time in 20 years that recognition has been awarded.

The International Hyperhidrosis Society (IHhS) is a US-based non-profit organisation dedicated to people living with hyperhidrosis, or excessive sweating. With this award, Sofdra® is ‘Recognized by the International Hyperhidrosis Society for Research & Rigor in Helping Combat Excessive Sweating™.’ The award highlights products, devices, and procedures validated by strong scientific and clinical evidence, rigorous testing, demonstrated efficacy and tolerability, and responsible marketing communications.

The recognition arrives at the start of Hyperhidrosis Awareness Month. IHhS has led the awareness month each November to spotlight a common medical condition that profoundly affects a patient’s quality of life.^[1] Hyperhidrosis can affect the face, hands, feet, underarms and other areas of the body. It affects more than 16 million Americans, yet many people do not recognise it as a medical condition, and only around half raise it with their doctor.

Once again, Botanix is supporting Hyperhidrosis Awareness Month with increased promotion in dermatology offices designed to raise awareness of primary axillary hyperhidrosis (excessive underarm sweating) and Sofdra. New materials placed in physicians’ waiting areas and exam rooms are designed to help patients self-identify their condition and prompt conversations about primary axillary hyperhidrosis between physicians and patients.

Botanix Chief Executive Officer Dr Howie McKibbon said:

‘We are honoured that Sofdra is a Recipient of the IHhS Seal of Recognition™ for Research & Rigor in Helping Combat Excessive Sweating™. IHhS has long been the champion of people living with hyperhidrosis, so this recognition carries real meaning for Botanix.

‘Hyperhidrosis Awareness Month is a reminder that excessive sweating is a medical condition, not a personal characteristic. Too many people live with it and go untreated. If this month encourages even a few more people to talk to their doctor, that is a win for the whole community.’

Botanix Pharmaceuticals Limited (ASX:BOT) is a dermatology company based in Phoenix (US), which has received FDA approval for Sofdra, its product for the treatment of primary axillary hyperhidrosis. Sofdra is the first and only new chemical entity approved by FDA to treat primary axillary hyperhidrosis and presents a novel, safe and effective solution for patients who have lacked treatment options for this socially challenging medical condition.

To learn more, please visit: www.botanixpharma.com